Holen Sie sich die Stockscreener-App
3.08
34.50%
0.79
Handel nachbörslich:
3.06
-0.02
-0.65%
Schlusskurs vom Vortag:
$2.29
Offen:
$2.45
24-Stunden-Volumen:
7.72M
Relative Volume:
3.06
Marktkapitalisierung:
$257.84M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-1.0694
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
+21.74%
1M Leistung:
+6.94%
6M Leistung:
+150.41%
1J Leistung:
-22.81%
1-Tages-Spanne:
$2.44
$3.17
1-Wochen-Bereich:
$2.07
$3.17
52-Wochen-Spanne:
$0.9101
$4.19
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.08 | 184.17M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine’s SWOT analysis: gene editing stock faces challenges, opportunities - Investing.com
Can Editas Medicine Inc. Regain Momentum After BreakdownQuarterly Profit Review & Precise Buy Zone Identification - 선데이타임즈
Baird raises Editas Medicine stock price target to $6 on pipeline progress - Investing.com UK
Editas: Q2 Earnings Snapshot - New Haven Register
Editas Medicine 2025 Q2 Earnings Narrows Losses Amid Revenue Surge - AInvest
Editas Medicine's Q2 Performance: Assessing Progress Amid Financial Challenges - AInvest
Editas Medicine Misses Expectations But Stays Focused On The Future - Finimize
Editas Medicine earnings missed by $0.23, revenue topped estimates - Investing.com Canada
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Editas Medicine posts Q2 net loss of $53.2 mln - MarketScreener
Editas Medicine Q2 2025: On track to file IND by mid-2026, proof-of-concept by year-end. - AInvest
Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewswire
Editas Medicine Reports Q2 2025 Results, Advances Gene Editing Programs - AInvest
Editas Medicine narrows losses as Bristol Myers Squibb partnership hits key milestone - Stock Titan
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Bought by XTX Topco Ltd - MarketBeat
Published on: 2025-08-09 06:19:25 - Newser
Quantitative breakdown of Editas Medicine Inc. recent moveInvestment Timeline and ROI Summary Report - Newser
Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) PT at $4.70 - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) EVP Linda Burkly Sells 5,121 Shares - MarketBeat
What makes Editas Medicine Inc. stock price move sharplyExit Strategy Guide With Risk Control Plan - Newser
Editas Medicine SVP Parison Amy Sells 679 Shares at $2.58/Share. - AInvest
Evaluating Editas Medicine Inc. with trendline analysisAI Stock Movement Forecast with Accuracy - Newser
How Interest Rate Changes Impact Editas Medicine Inc. Stock PerformanceAI Entry Timing Prediction for Swing Traders - Newser
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Bank of New York Mellon Corp - Defense World
Can you recover from losses in Editas Medicine Inc.Free Early Breakout Entry Point Notifications - Newser
Editas Medicine EVP Sells Shares to Meet Tax Obligations - TradingView
Trendlines Converge — Decision Point for Editas Medicine Inc.Real Profit Trade Plan Suggestions Shared Widely - beatles.ru
Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Why is Editas Medicine Inc. stock attracting strong analyst attentionAccess powerful market insights for free - Jammu Links News
How strong is Editas Medicine Inc. company’s balance sheetConsistently superior profits - Jammu Links News
What are analysts’ price targets for Editas Medicine Inc. in the next 12 monthsUnlock powerful trading alerts for success - Jammu Links News
When is Editas Medicine Inc. stock expected to show significant growthGet alerts on top growth stocks daily - Jammu Links News
What institutional investors are buying Editas Medicine Inc. stockBuild wealth faster with disciplined trading - Jammu Links News
Should I hold or sell Editas Medicine Inc. stock in 2025Maximize your portfolio’s earning power - Jammu Links News
Is Editas Medicine Inc. a growth stock or a value stockHigh-profit stock alerts - Jammu Links News
Cwm LLC Has $55,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
What is Editas Medicine Inc. company’s growth strategyTriple-digit profit margins - Jammu Links News
What are the technical indicators suggesting about Editas Medicine Inc.Invest smarter with actionable trading signals - Jammu Links News
Is Editas Medicine Inc. stock overvalued or undervaluedAchieve consistent double-digit growth rates - Jammu Links News
What catalysts could drive Editas Medicine Inc. stock higher in 2025High-yield trading alerts - Jammu Links News
Editas Medicine Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
What are the key drivers behind the recent increase in EDIT's trading volume? - AInvest
What is the dividend policy of Editas Medicine Inc. stockTop Growth Alerts With Proven Results - Jammu Links News
Editas Medicine Outperforms Medical Sector This Year Despite Zacks Rank #2 - AInvest
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? - Yahoo Finance
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):